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Objective. The protein SLIT2 and its receptor ROBO1 regulate different cellular processes, such as proliferation, apoptosis,
and migration. In this study our aim is to understand the alterations of these genes during development of head and neck
squamous cell carcinoma (HNSCC).
Materials and Methods. First, molecular alterations of the genes were analyzed in 30 dysplastic lesions, 128 primary HNSCC
samples, and 1 HNSCC cell line. Then alterations were correlated with mRNA expression (n ¼ 22) and protein expression (n ¼
29). Finally, the alterations were correlated with different clinicopathologic parameters and clinical outcomes of the patients.
Results. ROBO1 had a comparatively high frequency of deletion (28.5%-54.2%) from dysplastic lesions and subsequent
clinical stages than did SLIT2 (16.6-27%). On the contrary, SLIT2 had a high frequency (56.6%-81.2%) of promoter
methylation from dysplastic lesions onward compared with ROBO1 (20%-32.8%). Interestingly, alterations of SLIT2 and
ROBO1 were high in dysplastic lesions (80%), followed by comparable frequencies (92.5%-95.3%) in subsequent stages of
tumor. Alterations of these genes showed concordance with their mRNA/protein expression and significant association with
poor patient outcome.
Conclusions. Our data suggest that inactivation of SLIT2 and/or ROBO1 is one of the early events in development of dysplastic
lesions of head and neck and has prognostic importance. (Oral Surg Oral Med Oral Pathol Oral Radiol 2015;119:202-212)Head and neck squamous cell carcinoma (HNSCC) is
the sixth most common cancer worldwide, and it ac-
counts for 30% to 40% of all cancer types in the Indian
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Open access under CC BY-NC-ND license.tobacco, betel-nut leaf quid, alcohol, and infection with
oncogenic-type human papillomavirus (HPV) 16 and
HPV-18 to the development of HNSCC.1,3 Despite new
treatment modalities such as radiotherapy and chemo-
therapy, HNSCC is associated with high rates of
recurrence and mortality, with 5-year survival rates of
approximately 50%.4 Therefore details of the genetic
and epigenetic events leading to development of
HNSCC should be analyzed to help design novel
diagnostic and therapeutic procedures that can be used
in the clinical management of the disease.
In a preliminary tumor progression model of
HNSCC, allelic loss in the chromosome 3p region was
suggested to be associated with the transition of hy-
perplasia to dysplasia.5 Our previous study of HNSCC
in Indian patients found a high frequency of loss of
heterozygosity (LOH) in the chromosome 3p12-13 re-
gion and its association with the development of
dysplastic lesions.6 Chromosome 3p12-13 harbors
a candidate gene Roundabout1 or Deleted in UStatement of Clinical Relevance
In the analysis of alterations of SLIT2 and its re-
ceptor ROBO1 in the development of head and neck
squamous cell carcinoma (HNSCC), frequent inac-
tivation of these genes were evident in head and
neck lesions. Alterations of these genes were deter-
minant of poor patient outcome.
Table I. Clinicopathologic features of 158 head and
neck lesions
Clinical features
Number of samples
(n ¼ 158) (n%)
HPV-16/HPV-18
positivity (%)
Age group
20-30 3 (1.8) 0 (0)
31-40 29 (18.3) 14 (48.2)
41-50 43 (27.2) 22 (51.1)
51-70 83 (52.5) 49 (59)
Primary sites
BM 106 (67.08) 58 (54.7)
ALV 22 (13.9) 11 (50)
Sex TNG 30 (18.9) 16 (53.3)
Male 116 (73.4) 63 (54.3)
Female 42 (26.6) 22 (52.3)
Tumor stage
Mild dysplasia 9 (5.6) 3 (33.3)
Moderate dysplasia 14 (8.8) 7 (50)
Severe dysplasia 7 (4.4) 3 (42.8)
TNM stage I 7 (4.4) 1 (14.2)
TNM stage II 37 (23.4) 22 (59.4)
TNM stage III 44 (27.8) 26 (59)
TNM stage IV 40 (25.3) 23 (57)
Tumor differentiation
WDSCC 80 (50.6) 42 (52.5)
MDSCC 44 (27.8) 25 (56.8)
PDSCC 4 (2.5) 4 (100)
Lymph node
Positive 44 (27.8) 24 (54)
Negative 84 (53.1) 47 (55.9)
Etiologic factor
Tobacco þ* 125 (79.1) 65 (52)
Tobacco  33 (20.8) 20 (60.6)
Alcohol þ 16 (10.1) 7 (43.7)
Alcohol  142 (89.8) 78 (54.9)
HPV-16 80 (50.6) d
HPV-18 5 (3.1) d
ALV, alveolus; BM, buccal mucosa; HPV, human papillomavirus;
TNG, tongue; TNM, tumor node metastasis; MDSCC, moderately
differentiated squamous cell carcinoma; PDSCC, poorly differentiated
squamous cell carcinoma; WDSCC, well-differentiated squamous cell
carcinoma.
*Smoking or chewing tobacco or both.
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molog gene that encodes a member of the neural cell
adhesion molecule (NCAM) in the immunoglobulin
(Ig) superfamily.7 Mice harboring deletions of exon 2
of ROBO1 spontaneously developed bronchial epithe-
lial hyperplasia, indicating it as a candidate tumor
suppressor gene (TSG).8 Our previous study also found
a high frequency of molecular alterations (deletion/
methylation) and concordant reduced expression of
ROBO1 in head and neck lesions, indicating importance
of this gene in the development of HNSCC.7
ROBO1 serves as a receptor of the SLIT2-ROBO1
signaling pathway. Drosophila homolog SLIT2 homology
2 (SLIT2) protein contains a unique N-terminal tandem of
4 leucine-rich repeat (LRR) domains. The gene SLIT2 is
located at chromosome 4p15.31 region. The LRR domain
of SLIT2 interacts with the extracellular Ig domain ofROBO1 and this inhibits downstream signaling network,
resulting in cell cycle arrest at the G1-S transition, in-
duction of apoptosis, inhibition of cell migration, and
invasion.9,10 Inactivation of SLIT2 leads to the devel-
opment of lung adenocarcinoma and lymphoma in mice,
indicating it as a candidate TSG.11 Reduced expression
of SLIT2 has also been reported in carcinomas of the
colon, cervix, and lung.12-15 Therefore SLIT2 and
ROBO1 are 2 important candidate TSGs of the SLIT2-
ROBO1 signaling pathway and inactivation of either of
these candidate genes might lead to inactivation of the
said signaling pathway, resulting in development of
malignant tumors. To the best of our knowledge, alter-
ations of SLIT2 have not yet been studied in HNSCC,
although frequent deletion of the chromosomal region
(4p15.31) harboring the candidate gene has been re-
ported in an HNSCC cell line.16
Thus to explore the role of the SLIT2-ROBO1
signaling pathway in the development of HNSCC, at-
tempts have been made to analyze the alterations (dele-
tion, methylation, mutation, and expression) of SLIT2
and ROBO1 in same set of dysplastic and HNSCC
samples of Indian patients and in an HNSCC cell line.
The molecular alterations were then correlated with
various clinicopathologic parameters and with disease
outcomes. Our data revealed that frequent alterations of
SLIT2 in addition to ROBO1 of the SLIT2-ROBO1
signaling pathway were associated with the develop-
ment of HNSCC. The alterations of SLIT2 and ROBO1,
along with less advanced clinical stage, were de-
terminants of poor prognosis of the disease.
MATERIALS AND METHODS
Patient population, tumor tissues, and cell line
The Institutional Ethical Board of Chittaranjan National
Cancer Institute, Kolkata, India, approved the usage of
human specimens in this study. The tumor specimens
were collected from the hospital section of Chittaranjan
National Cancer Institute, Kolkata, after obtaining
written, informed consent from the concerned patients,
in stipulated format, approved by the Institutional
Ethical Board of Chittaranjan National Cancer Institute,
Kolkata, India. The patients are from eastern India. A
total of 158 primary tumor tissue samples from oral
cavities without any previous treatment as well as
matched adjacent normal tissues were collected
(Table I). After surgery, all the patients received con-
ventional chemotherapy or radiotherapy or both. Only
primary tumor samples from oral cavity were collected.
All these tumors were graded and staged according to
the Union for International Cancer Control (UICC)
tumor node metastasis (TNM) classiﬁcation. Patient’s
clinicopathologic information (n ¼ 158) is presented in
Table I and Supplemental Table SI (available on the
journal’s website at www.oooojournal.net). Samples
Fig. 1. Tumor samples usage. Schematic representation of the usage of primary head and neck squamous cell carcinoma (HNSCC)
tumor in different analyses. Del, deletion analysis; HNSCC, head and neck squamous cell carcinoma; IHC, immunohistochemical
analysis;Meth, methylation analysis;Mut, mutation analysis by SSCP; n, sample number; QRT-PCR, real-time PCR quantiﬁcation.
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use. Portions of the freshly operated tissues of some
samples (n ¼ 22) were directly collected in TRIzol
reagent (Invitrogen, Carlsbad, CA, USA) for RNA
isolation, and also parts of some samples (n ¼ 29) were
ﬁxed in formalin and embedded in parafﬁn for immu-
nohistochemical analysis. The cell line UPCI:SCC084,
isolated from 52-year-old male Caucasian oral cancer
patient with pathologic stage T2 N2 B and with
smoking and alcohol habit,17 was kindly provided by
Prof. Susanne M. Gollin (University of Pittsburgh, PA,
USA). Summary of the total samples used in different
experiments is shown in Figure 1.
Microdissection and DNA extraction
The contaminant normal cells in the head and neck
lesions were removed by microdissection procedure
from cryosections (5 mm) using surgical knives under a
dissecting microscope (Leica MZ16, Wetzlar, Ger-
many). The representative sections from different re-
gions of the specimens were stained with hematoxylin
and eosin for diagnosis as well as for marking of the
dysplastic epithelium/tumor-rich regions. The samples
containing >60% dysplastic epithelium/tumor cells
were taken for isolation of DNA according to the
standard procedure.18 High-molecular-weight DNA
was extracted by proteinase-K digestion, followed by
phenol-chloroform extraction.19,20
Deletion analysis
Deletion analysis of SLIT2 and ROBO1 loci was done in
30 dysplastic head and neck lesions and 128 HNSCC
samples, using microsatellite markers (Supplemental
Table SII; available on the journal’s website at www.
oooojournal.net). Among the samples, deletion of
ROBO1 has been reported in the 25 dysplastic lesions
and 72 HNSCC samples in our previous study.7 In mi-
crosatellite-based deletion mapping, polymerase chainreaction (PCR) containing [g-P32] ATP end labeled
forward primer was done in a 20 mL reaction volume
according to the method described by Tripathi et al.21
The microsatellite markers were selected on the basis of
their map positions and heterozygosity (Ensembl
Release 49, http://www.ensembl.org, 2008). For dele-
tion analysis of ROBO1, an intragenic microsatellite
marker D3S1274 located in intron-2 and another mi-
crosatellite marker D3S3507 located at 89 Kb down-
stream were used. For deletion analysis of SLIT2, an
intragenic microsatellite marker D4S1372 and another
marker D4S1546 located at 145 kb downstream from
SLIT2 were used. Because D4S1372 was homozygous,
multiplex PCR was performed with a control marker
D4S2364 having infrequent alterations, as reported by
Singh et al.22 Scoring of loss of heterozygosity [LOH]/
deletion and microsatellite size alteration [MA] for
informative and noninformative markers were done
according to the method described by Tripathi et al.21
Promoter methylation analysis
The promoter methylation of SLIT2 and ROBO1 genes
was analyzed in 30 dysplastic head and neck lesions and
128 HNSCC and corresponding adjacent normal sam-
ples by PCR-based methylation-sensitive restriction
analysis (MSRA) using MspI/HpaII restriction enzymes
(Sibenzyme, Novosibirsk, Russia) as described previ-
ously.23,24 The data obtained by MSRA was validated
by methylation-speciﬁc PCR (MSP) in 25 randomly
selected samples after bisulphite modiﬁcation of the
genomic DNA according to the standard procedure.25
Details of primer sequences are listed in Supplemental
Table SII.
Mutation analysis
The mutation of SLIT2 and ROBO1 was screened in 30
dysplastic head and neck lesions, 128 HNSCC samples,
and on 1 oral cancer cell line by single-strand
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radio labeled [a-P32] deoxycytidine 50-triphosphate
(dCTP) as described by Tripathi el al.26 The SLIT2-
ROBO1 interacting domains encompassing exons 9 to
14 of SLIT2 and exons 2 to 4 of ROBO1 were selected
for mutation analysis. All the primers used in this
experiment are listed in Supplemental Table SII. Elec-
trophoresis was done in 6% nondenaturing poly-
acrylamide gel with 10% glycerol at 2 W overnight and
autoradiographed on X-ray ﬁlm (Kodak, Rochester,
NY, USA). Sequencing of both strands of samples
showing abnormal band shift was done using 3130xl
Genetic Analyzer (Applied Biosystems, Foster City,
CA, USA).mRNA expression analysis
mRNA expression of SLIT2 and ROBO1 was analyzed
in only 22 primary HNSCC samples (because of
availability of limited amount of primary tissues after
surgery), corresponding adjacent normal tissues, and
HNSCC cell line SCC084 using primers, as mentioned
in Supplemental Table SII. Total RNA was isolated
from samples using TRIzol reagent according to the
manufacturer’s protocol (Invitrogen, Carlsbad, CA,
USA). Reverse transcription reaction was performed
with 1 mg of total RNA using Random Hexamers
(Invitrogen) and M-MuLV Reverse Transcriptase
(Promega, Madison, WI, USA). Relative expression of
the gene was measured by real-time quantitation using
b2-microglobulin (B2M) as an internal control.24Cell line and 5-Aza-deoxycytidine (5-aza-dc)
treatment
As in our previous study, the 5-aza-dc concentration
was taken up to 20 mM.23 Subconﬂuent cultures of
SCC084 were treated with 10 mM and 20 mM 5-aza-dc
(Sigma-Aldrich, St. Louis, MO, USA) for 5 days.
Controls without 5-aza-dc were cultured concomitantly
in the same manner. After completion of treatment,
cells were harvested, followed by RNA isolation,
cDNA preparation, and real-time quantitation using the
Power SYBR Green PCR assay kit according to man-
ufacturer’s protocol (Applied Biosystems, Foster City,
CA, USA).Immunohistochemical / immunocytochemical
analysis
Protein expression of SLIT2 and ROBO1 was assessed
by immunohistochemical (IHC) analysis in only 25
head and neck lesions and adjacent normal samples
(because of limited availability of primary tissue after
surgery) and by immunocytochemical (ICC) analysis in
the SCC084 cell line according to standard protocol.23The tissue sections were incubated overnight at 4 C
with primary antibodies SLIT2 (sc-16619) and ROBO1
(sc-16611) (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) used at a dilution of 1:80. HRP-conjugated
rabbit anti-goat secondary antibody (sc-2768) was
added at 1:500 dilutions. The slides were developed
using 3-30 diaminobenzidine (DAB, Santa Cruz
Biotechnology) as the chromogen, counterstained with
hematoxylin, and photographed with a bright-ﬁeld mi-
croscope (Leica DM1000, Wetzlar, Germany). The
staining intensity (1 ¼ weak, 2 ¼ moderate, 3 ¼ strong)
and the percentage of positive cells (<1 ¼ 0, 1-20 ¼ 1,
20-50 ¼ 2, 50-80 ¼ 3, >80 ¼ 4) were detected by 2
independent observers, and by combining the 2 scores,
ﬁnal evaluation of expression was done (0-2 ¼ low,
3-4 ¼ intermediate, 5-7 ¼ high).27
For ICC analysis, cover slip culture of the SCC084
cell line was reacted with the same dilution of primary
antibodies of these proteins after permeabilization
with 0.5% Triton X-100 and blocking with 5% bovine
serum albumin (BSA). After washing, the coverslips
were incubated with corresponding FITC-conjugated
rabbit anti-goat secondary antibody (sc-2777) at
1:500 dilutions and mounted with glycerol after
thorough washing. Imaging of the cover slip was
performed with a semiconfocal laser dissecting mi-
croscope using Apotome with Axiovision 4.8.1 Soft-
ware (LCM, Carl Zeiss, Göttingen, Germany). All
the chemicals were purchased from Santa Cruz
Biotechnology.
Detection of HPV-16 and HPV-18
HPV infection in the head and neck lesions was
detected by PCR using primers (MY09 and MY11)
from the consensus L1 region followed by typing of
HPV-16 and HPV-18 in the L1 positive samples as
described by Ghosh et al.2Statistical analysis
Fisher’s exact test was used to determine the association
between tumors’ genetic proﬁle and different clinico-
pathologic features. All statistical tests were 2-sided and
considered signiﬁcant at P < .05. Survival curves were
calculated according to the Kaplan-Meier method in
128 HNSCC samples. After sample collection, follow-
up data on the patients were taken for up to 5 years and
overall survival of the patients was assessed with ge-
netic alterations. According to the hospital-based cancer
registry, all the deaths were as a result of cancer-related
complications. For this method, P values were evalu-
ated by the log rank test for censored survival data. A
Cox proportional hazards regression model was used to
test the statistical signiﬁcance of several potential
prognostic factors, such as clinical stage, tumor site,
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candidate TSGs, that were jointly predictive of overall
survival of the patients. From this model we estimated
the hazard ratio (HR) for each potential prognostic
factor with a 95% conﬁdence interval (CI) in multi-
variate fashion. All the statistical analysis was per-
formed using statistical programs Epi Info 6.04d and
SPSS 10.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Analysis of HPV infection
Infection by HPV is considered one of the important
etiologic factors for HNSCC development. HPV typing
was done in this study to analyze the frequency of high-
risk HPVs in our samples. HPV DNA was detected in
53.7% (85/158) of the tumors (Table I). Among the
HPV-positive samples, 94.1% (80/85) were HPV-16
positive and 5.8% (5/85) were HPV-18 positive.
Deletion analysis of SLIT2 and ROBO1 loci
In dysplastic lesions, a comparatively higher frequency
of deletion was seen in ROBO1 (28.5%, 8/28) locus than
in SLIT2 (16.6%, 5/30) (Supplemental Table SI). In
HNSCC samples, the deletion frequency of ROBO1 was
comparable up to stages I and II (28.50%, 10/35), fol-
lowed by signiﬁcant increase (P¼ .003) in stages III and
IV (48.6%-54.2%) (Figure 2A, B, C, F). On the other
hand, the deletion frequency of SLIT2 (18%-27%) did not
change signiﬁcantly during progression of tumor. Low
frequency of microsatellite size alterations (MAs) was
found in both SLIT2 and ROBO1 (6.6% to 10%) loci
during progression of the tumor (Supplemental Table SI).
Deletions of SLIT2 and ROBO1 had no signiﬁcant as-
sociation (Supplemental Table SIII; available on the
journal’s website at www.oooojournal.net).
Promoter methylation analysis of SLIT2 and
ROBO1
In methylation analysis, concordance was found be-
tween MSRA and MSP analyses (Supplemental
Table SIV; available on the journal’s website at www.
oooojournal.net). No promoter methylation was detec-
ted in the adjacent normal tissues of the samples.
However, in the dysplastic lesions, higher frequency of
methylation was found in SLIT2 (56.6%, 17/30) than in
ROBO1 (20%, 6/30) (Supplemental Table SI). During
progression of HNSCC, the methylation frequency of
SLIT2 increased in subsequent stages (75%-81.2%),
whereas in ROBO1 the methylation frequency did not
change signiﬁcantly (27.2%-32.5%) (Figure 2E, F, G).
Promoter methylation of both SLIT2 and ROBO1 was
found in SCC084 (Supplemental Table S1). No sig-
niﬁcant association was found between the methylation
status of SLIT2 and ROBO1 in dysplastic lesions, but
signiﬁcant association was found in HNSCC samples(P ¼ .003) (Supplemental Table SV; available on the
journal’s website at www.oooojournal.net). This in-
dicates that methylation of SLIT2 might have some
cooperativity in ROBO1 methylation in HNSCC.
Mutation analysis of SLIT2 and ROBO1 interacting
domain
Mutation in SLIT2-ROBO1 interacting domain might
disrupt the association of proteins, resulting in deregu-
lation of the signaling network. Thusmutation analysis in
SLIT2 andROBO1 interacting domainswere analyzed by
SSCP analysis (Supplemental Figure S1; available on the
journal’s website at www.oooojournal.net). No altered
bandwas observed in both SLIT2 andROBO1 interacting
regions. Thus mutation in SLIT2-ROBO1 interacting
domains seemed to be a rare event in HNSCC.Overall alterations of SLIT2 and ROBO1
The overall alterations (deletion/methylation) of the
genes in the tumors were: Dysplasia: SLIT2 (63.3%; 19/
30), ROBO1 (43.3%; 13/30); HNSCC: SLIT2 (84.3%;
108/128), ROBO1 (57.8%; 74/128). In HNSCC samples,
overall alteration frequency of SLIT2 was almost con-
stant in subsequent stages of the disease. The overall
alteration frequency of ROBO1 was comparable up to
stages I and II (43.1%, 19/44), followed by signiﬁcant
increase (P ¼ .01) in stages III and IV (63.6%-67.5%)
(Figure 2H, Supplemental Table SVI; available on the
journal’s website at www.oooojournal.net). However,
alteration of the gene was not associated with nodal sta-
tus, HPV infection, or tobacco habit. The majority of the
tumors (80.3%; 127/158) had epigenetic/genetic alter-
ations in at least 1 of the genes, with high frequency of
alterations in dysplastic lesions (80%, 24/30), followed
by comparable frequencies (92.5%-95.3%) during pro-
gression of the tumor (Figure 2G, Supplemental
Table SI). This suggests that deregulation of the SLIT2-
ROBO1 signaling is one of the early events in the
development of this tumor.mRNA expression of SLIT2 and ROBO1 in HNSCC
In quantitative RT-PCR analysis, SLIT2 and ROBO1 had
greater than 2-fold reductions in mRNA expression in
91% (20/22) and 54% (12/22) of tumors, respectively
(Figure 3A, B). The frequency of the samples with mean
fold reduction in mRNA expression of SLIT2 was
greater than that of ROBO1. Both SLIT2 and ROBO1
mRNA expression was downregulated in the SCC084
cell line. Thus, mRNA expression of SLIT2 and ROBO1
was severely impaired in HNSCC.
To conﬁrm inactivation of the SLIT2 and ROBO1
because of methylation, a demethylation experiment was
performed by treatment of 5-aza-dc in the SCC084 cell
line. Upregulation of SLIT2 and ROBO1 mRNA
Fig. 2. Molecular alterations of SLIT2 and ROBO1. Representative autoradiographs showed the deletion and microsatellite size
alteration (MA) of ROBO1 and SLIT2 locus. (A) Loss of heterozygosity (LOH) at D3S3507 in sample 442; (B) MA-I of the
microsatellite at D3S1274 in sample 2073; (C) hemizygous deletion (HEM) at D4S1372 in sample 3070. The marker D4S2364 was
used as internal control for multiplex PCR. (D) Representative gel electrophorogram showing the methylation status of SLIT2 in
tumor samples and in corresponding normal sample (i) by methylation-sensitive restriction analysis (MSRA) and (ii) validated by
methylation-speciﬁc PCR (MSP) after bisulphate modiﬁcation of DNA. (E) Representative gel electrophorogram showing the
methylation status of ROBO1 in tumor samples and in corresponding normal sample (i) by MSRA and (ii) validated by MSP. The
samples 219 T and 5114 T had the methylation-speciﬁc PCR band, but 219 N, 5114 N, 51 TN, and 2035 TN had an unmethylation-
speciﬁc PCR band. K1 and K2: controls for DNA digestion and integrity, respectively; H, amplicon obtained with primer for HpaII
digested DNA; M, amplicon obtained with primer for MspI digested DNA; U, amplicon obtained with primer for undigested DNA.
u; amplicon obtained with primer for modiﬁed unmethylated DNA; m, amplicon obtained with primer for modiﬁed methylated
DNA; T, tumor DNA; N, corresponding normal tissue DNA. (F) Bar diagram indicates the stage-wise deletion pattern of SLIT2 and
ROBO1 locus. Star marks indicate the signiﬁcant difference. (G) Bar diagram shows the stage-wise methylation pattern of SLIT2
and ROBO1. (H) Bar diagram represents the stage-wise overall alteration pattern of individual genes and SLIT2-ROBO1 receptor
ligand.
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Fig. 3. Expression analysis of SLIT2 andROBO1. Quantitative RT-PCR indicatingmRNAexpression pattern of (A) SLIT2 (B)ROBO1
in HNSCC samples and cell line. Bars represent the gene expression normalized to b2-microglobulin and relative to corresponding
adjacent normal tissues, using 2ddCt method. X-axis indicates the sample numbers. (C) Bar diagram indicates the effect of 5-aza-dc
treatment on SLIT2 and ROBO1 expression in SCC084 cell line. The expression level of both SLIT2 and ROBO1 was increased in the
cell line. (D) (i) Differential cytoplasmic expression of SLIT2 in the basal lining/parabasal cells of normal oral epithelium and primary
HNSCC samples were found. Spinous layer had high expression of SLIT2. Tumor sample 51 T had high expression and 3910 T had low
expression of SLIT2. (ii) Distinct membrane expression of ROBO1 was found in parabasal/spinous layer cells and cytoplasmic
expression in basal lining of normal oral epithelium. Tumor sample 3292 had high cytoplasmic and membrane expression of ROBO1.
Sample 219 T had low expression of the gene and tumor samples. Magniﬁcation of tissue samples is 40. Scale bar represent 50 mm.
Black arrowhead indicates the localization of the protein. Dþ/, deletion present/absent; Mþ/, methylation present/absent.
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Fig. 4. Immunocytochemical (ICC) analysis of SLIT2 and ROBO1. Overnight subconﬂuent cover slip culture of SCC084 cell line
was ﬁxed with 100% methanol and protein expression of the genes was analyzed by ICC. (A) ROBO1 had reduced cytoplasmic
expression in SCC084. (B) SLIT2 expression was low with membrane aggregation in SCC084. Green arrows indicate the protein
expression and localization. Mþ/, methylation present/absent. (C) Kaplan-Meier analysis of survival (up to 5 years) of HNSCC
patients. Alteration of both SLIT2 and ROBO1 was signiﬁcantly associated with poor overall survival (OS) with log rank
P ¼ .0001. Survival time was deﬁned as the time from the date of surgery to the date of last follow-up (up to 5 years). n, number of
samples; SþRþ, patients with genetic/epigenetic alteration of both SLIT2 and ROBO1; SþR, patients with genetic/epigenetic
alteration of SLIT2 without ROBO1 alteration; SeRþ, patients with genetic/epigenetic alteration of ROBO1 without SLIT2
alteration; SeR, patients having no alteration of SLIT2 and ROBO1.
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in the cell line with respect to untreated controls. In
presence of 5-aza-dc (20 mm), About 9 fold activation of
SLIT2 and 18 fold activation ofROBO1were observed in
SCC084 (Figure 3C). Thus promoter methylation might
be one of the inactivating mechanisms of reduced
expression of the genes.Analysis of SLIT2 and ROBO1 protein expression
In normal oral epithelium, diffuse low cytoplasmic
expression of SLIT2 in the basal layer and high cyto-
plasmic expression in the spinous layer were noted
(Figure 3D), whereas ROBO1 had diffuse cytoplasmic
expression in the basal/parabasal layer and distinct
membrane expression in spinous layer (Figure 3D). In
primary tumors, moderate/low expression of SLIT2 and
ROBO1 was found in 89% (26/29) and 58% (17/29) ofsamples, respectively (Figure 4A). Reduced cyto-
plasmic expression of ROBO1 was observed in
SCC084. Reduced cytosolic expression of SLIT2 was
seen in SCC084 with discrete membrane foci
(Figure 4B). This might be due to some modiﬁcations
of these receptors and ligands in the cell line leading to
their aggregation on the nucleus and membrane.
In correlation analysis, signiﬁcant association was
found between reduced expression (mRNA/proteins) of
the genes and their molecular alterations (Table II).Clinicopathologic association of SLIT2 and ROBO1
The alterations of SLIT2 and ROBO1 were correlated
with the clinicopathologic/survival parameters in order
to uncover their prognostic signiﬁcance (if any) for
early diagnosis and prediction of patient outcome. The
Kaplan-Meier (K-M) analysis revealed signiﬁcantly
Table II. Correlation of molecular alterations with RNA/protein expression of the genes SLIT2 and ROBO1
SLIT2
Node HPV
ROBO1
expression
Genetic alteration
expression
Genetic alterationRNA Protein RNA Protein
HNSCC cell line
SCC084 YY þ Mþ ND 16/18 YY þ Mþ
Dysplasia
L61 ND þþþ DM ND 16 ND þ DþMþ
L53 ND þ DMþ ND A ND þþ DMþ
L60 ND þþ DMþ ND 16 ND þ DþM
Tumor samples
3689 YY þþ DMþ þ A Y þ DMþ
7077 Y þþ DMþ e 16 Normal þþþ DM
2649 YY þþ DMþ e 16 Normal þþ DM
4465 YY þþ DMþ þ A Y þþ DMþ
3371 Y þþ DMþ e A YY þ DMþ
315 Y þþ DMþ þ A Normal þþþ DM
3187 YY þ DþMþ e 16 YY þþ DMþ
5999 Y þ DMþ e 16 Normal þþþ DM
6835 Y þþ DMþ e A YY þ DþMþ
403 YY þþ DMþ e 16 Normal þþþ DM
3910 YY þ DþMþ e 16 Normal þþþ DM
2496 YY þþ DMþ e A Y þþ DMþ
4892 YY þþ DMþ e A Normal þþþ DM
2935 YY þþ DMþ þ 16 YY þþ DMþ
5232 YY þþ DMþ þ A Y þ DMþ
3484 Y þ DMþ þ 16 YY þþ DMþ
3489 YY þþ DMþ e 18 YY þ DMþ
51 Normal þþ DM þ A Normal þþþ DM
4283 Y þþ DMþ þ A YY þ DþMþ
2333 Y þþ DMþ þ A YY þ DþM
1416 YY þ DMþ þ 16 YY þ DþMþ
4546 Y þþ DMþ e A Normal þþþ DM
P value .0085 > .001
A, HPV absent; Dþ/, deletion (microsatellite size alteration [MA], loss of heterozygosity [LOH]) positive/negative; Mþ/, methylation positive/
negative; ND, not determined; HNSCC, head and neck squamous cell carcinoma; 16/18, HPV-16/HPV-18; Y, decreased gene expression compared
with normal; þþþ, protein expression high; þþ, protein expression medium, þ, protein expression low.
Statistically signiﬁcant (P < .05).
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alterations of both SLIT2 and ROBO1 (log rank
P ¼ .0001) (Figure 4C). Interestingly, alterations of
either SLIT2 or ROBO1 also predicted poorer OS of the
patients than the patients having no alterations
(Figure 4C). The Cox regression analysis indicated that
alterations of SLIT2 (HR: 2.8117, CI: 1.4792-5.3444)
and ROBO1 (HR: 6.4368, CI: 3.8981-10.6290) with
lower clinical stage (HR: 0.7912, CI: 0.6346-0.9864) of
the disease were determinant of poor prognosis of
HNSCC patients (Table III), thereby enabling efﬁcient
classiﬁcation of the high-risk patients. Other clinico-
pathologic parameters, such as HPV, tobacco, alcohol,
and lymph node metastasis, have no signiﬁcant role in
prediction of clinical outcome over histologic grade and
alterations of both genes.
DISCUSSION
The aim of this study was to investigate the associ-
ation of ligand-receptor encoding genes SLIT2 andROBO1 with the development of HNSCC. Infrequent
deletion and high frequency of methylation of SLIT2
in dysplastic head and neck lesions followed by a
similar trend in invasive tumors (Figure 2) indicated
the importance of epigenetic alteration of the gene in
development of the disease. The 5-aza-dc experiment
in the UPCI:SCC084 cell line conﬁrmed the inacti-
vation of SLIT2 by promoter methylation (Figure 3C).
To our knowledge, no such study has yet been re-
ported in HNSCC. Frequent methylation of SLIT2 has
also been reported in premalignant and malignant
lesions of the cervix, lung, and colon13,28-30 and also
in glioma, ovarian carcinoma, and breast carci-
noma.12-15 In contrast to our data, high frequency of
deletion of SLIT2 has been reported in mesothelioma
and carcinomas of lung, breast, and cervix.13 The
differences in the genetic and epigenetic changes of
SLIT2 in HNSCC than other cancers might be due to
the differences in molecular pathogenesis of the
disease.
Table III. Multivariate analysis of SLIT2 and ROBO1
alterations in 128 HNSCC samples with different clin-
icopathologic parameters
Variables
Overall survival
P value HR 95% CI for HR
Histology .5365 1.1176 0.7855 - 1.5902
Stage .0374* 0.7912 0.6346 - 0.9864
HPV .1967 1.3003 0.8728 - 1.9371
Tobbaco .7944 0.9373 0.5761 - 1.5251
Alcohol .5267 1.2454 0.6312 - 2.4573
Node .6104 1.1335 0.6999 - 1.8359
SLIT2 ALT .0016* 2.8117 1.4792 - 5.3444
ROBO1 ALT < .00001* 6.4368 3.8981 - 10.6290
HPV, human papillomavirus; HR, hazard ratio.
* indicate statistically signiﬁcant values.
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than methylation in dysplastic and early invasive le-
sions, with signiﬁcant increase in later stages of tumor
progression (Figure 2F). This suggests association of
ROBO1 inactivation with the development and pro-
gression of the disease. Similarly, deletion seemed to be
predominant mechanism of inactivation of ROBO1 over
methylation in multiple malignancies such as glioma
and carcinomas of the lung, breast, and cervix.15,28,31
Absence of mutation in the LRR domain (ROBO1
interacting region) of SLIT2 and in Ig domain of
ROBO1 (SLIT2 interacting region) suggests mutation in
SLIT2-ROBO1 interacting domain is a rare event of
these genes in HNSCC. High frequency of overall
alteration of SLIT2 or ROBO1 in dysplastic lesions, and
comparable frequency in subsequent stages of the dis-
ease, indicate that alterations of SLIT2-ROBO1
signaling were relatively early to the cancer onset and
maintain the same levels of alterations during the tumor
progression.
Reduced expression (mRNA) of SLIT2 and ROBO1
in the majority of the primary tumors and HNSCC cell
line having deletion and/or methylation indicated the
importance of these mechanisms in gene inactivation
(Figure 3A, B, Table II). The concordance of expres-
sion status of the proteins (by IHC) with that of mRNA
also supported this phenomenon. Similar ﬁndings have
also been reported in carcinomas of the cervix, lung,
and breast13,15,28,29
In our previous study of ROBO1 alteration (deletion/
methylation) in HNSCC development, frequent alter-
ation of ROBO1 was seen in dysplastic and invasive
lesions.7 In this study, to understand the association of
SLIT2-ROBO1 in the development of HNSCC some
common samples of dysplastic lesions (n ¼ 25) and
invasive lesions (n ¼ 72) of the previous study were
used along with some freshly collected samples
(dysplastic lesions: 5; invasive lesions: 56). The
ROBO1 alteration had concordance with the previousstudy. The alterations of SLIT2 and ROBO1 were high
(80%) and did not change signiﬁcantly in later stages of
tumor development, indicating the importance of this
pathway in the development of HNSCC (Figure 2H).
The association of SLIT2 and ROBO1 inactivation with
poor patient outcome (Figure 4C) suggests their prog-
nostic importance. This has been supported by multi-
variate analysis where poor prognosis of the patients
was found to have alterations of both SLIT2 and
ROBO1 in the tumors at early clinical stages (Table III).
It was evident that inactivation of SLIT2-ROBO1
pathway led to the accumulation of activated CDC42-
GTP complex, resulting in (i) inactivation of EGFR
degradation through endocytosis, (ii) promotion of cell
migration by losing the interaction between E-cadherin
and b-catenin, (iii) increase of actin polymerization, and
so on (Supplemental Figure S2; available on the jour-
nal’s website at www.oooojournal.net).9,32,33 This
might cause deregulation of different cellular processes
such as proliferation, apoptosis, and cell motility,9
leading to selection of highly malignant clones with
adverse prognosis.
CONCLUSIONS
Our study found that frequent alterations of SLIT2, in
addition to ROBO1, of the SLIT2-ROBO1 signaling
pathway was associated with the development of
HNSCC. Detailed analysis of this pathway is warranted
to ﬁnd key molecular targets for development of
effective therapeutic strategies for management of the
disease.
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